Inflammatory Bowel Disease Market By Product Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Inflammatory Bowel Disease Market
Inflammatory Bowel Disease Market: By Product Type (Aminosalicylates, Antibiotics, Corticosteroids, Biologic therapies, & Immunomodulators), By Application (Therapeutic & Diagnostics), By Disease Condition & Geography-Forecast (2016-2021)
Report Code : HCR 0225
Published On: 03 February, 2016   Updated On: 03 February, 2016

  • Report Description
  • Table of Contents
  • Customization Options
Inflammatory bowel disease (IBD) related to the digestive systems of the human being which can be identified by chronic inflammation of all or part of your digestive tract. This disease primarily includes ulcerative colitis and Crohn's disease.

This report identifies the Inflammatory Bowel Disease market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Inflammatory Bowel Disease market.
 
Inflammatory Bowel Disease Market

Globally North America dominated the market for Inflammatory Bowel Disease in 2015 high awareness about IBD in the region along with deep penetration and easy availability of treatments for such disease in highly systematic and developed healthcare infrastructure in the region. North America was followed by Europe as the second largest regional market for Inflammatory Bowel Disease. However, Asia-Pacific is expected to be fastest growing regional segment during the period of study due to fast developing healthcare infrastructure in the regional markets such as India and China along with increasing awareness about such diseases in the population.
  • This report on global Inflammatory Bowel Disease covers different type of inflammatory bowel disease applications, disease condition and products of inflammatory bowel disease availability in the current market place and market size in various geographical regions.
  • On the basis of disease applications of Inflammatory Bowel Disease, this report covers two major applications of Inflammatory Bowel Disease, Two major applications inflammatory bowel disease covered in this report are as follows: Therapeutic and Diagnostics
  • On the basis of disease condition of Inflammatory Bowel Disease, this report covers two major disease condition of Inflammatory Bowel Disease, Two major conditions of  inflammatory bowel disease covered in this report are as follows: Crohns disease and Ulcerative colitis
  • This reports is also classified on the basis of products availability for Inflammatory Bowel Disease in the current market place, this report covers five major product type available for Inflammatory Bowel Disease, some of the major types covered in this report are as follows: Aminosalicylates, Antibiotics, Corticosteroids, Biologic therapies (biological drugs) and  Immunomodulators
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for Inflammatory Bowel Disease in each of the region.

This report identifies all the major companies operating in the global Inflammatory Bowel Disease market. Some of the major companies’ profiles in detail are as follows:
  • Bristol-Myers Squibb Company
  • Baxter International, Inc.
  • Johnson & Johnson
  • Sanofi-Aventis LLC
  • Abbott Laboratories
1. Inflammatory Bowel Disease– Market Overview
2. Executive Summary
3. Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Inflammatory Bowel Disease– Market Forces
   4.1. Drivers
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Inflammatory Bowel Disease– Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Inflammatory Bowel Disease Market, By Application
   6.1. Therapeutic
   6.2. Diagnostics
7. Inflammatory Bowel Disease Market, By Disease Condition
   7.1. Crohns disease
   7.2. Ulcerative colitis
8. Inflammatory Bowel Disease Market, By Product Type
   8.1. Aminosalicylates
   8.2. Antibiotics
   8.3. Corticosteroids
   8.4. Biologic therapies (biological drugs)
   8.5. Immunomodulators
9. Inflammatory Bowel Disease Market, By Geography
   9.1. Europe
      9.1.1. Germany
      9.1.2. France
      9.1.3. Italy
      9.1.4. Spain
      9.1.5. Russia
      9.1.6. U.K.
      9.1.7. Rest of Europe
   9.2. Asia Pacific
      9.2.1. China
      9.2.2. India
      9.2.3. Japan
      9.2.4. South Korea
      9.2.5. Rest of Asia-Pacific
   9.3. North America
      9.3.1. U.S.
      9.3.2. Canada
      9.3.3. Mexico
   9.4. Rest of the World (RoW)
      9.4.1. Brazil
      9.4.2. Rest of RoW
10. Inflammatory Bowel Disease– Market Entropy
   10.1. Expansion
   10.2. Technological Developments
   10.3. Merger & Acquisitions, and Joint Ventures
   10.4. Supply- Contract
11. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
   11.1. Bristol-Myers Squibb Company
   11.2. Baxter International, Inc.
   11.3. Johnson & Johnson
   11.4. Sanofi-Aventis LLC
   11.5. Abbott Laboratories
   11.6. Pluristem Therapeutics, Inc.
   11.7. Pfizer, Inc.
   11.8. AstraZeneca PLC
   11.9. Cephalon, Inc.
   11.10. Amgen, Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12. Appendix

   12.1. Abbreviations
   12.2. Sources
   12.3. Research Methodology
   12.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll